Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

199.32B

Market cap199.32B

Price-Earnings ratio

10.41

Price-Earnings ratio10.41

Dividend yield

2.77%

Dividend yield2.77%

Average volume

13.01M

Average volume13.01M

High today

$45.18

High today$45.18

Low today

$43.72

Low today$43.72

Open price

$44.61

Open price$44.61

Volume

10.79M

Volume10.79M

52 Week high

$81.44

52 Week high$81.44

52 Week low

$35.12

52 Week low$35.12

NVO News

Simply Wall St 53m

Assessing Novo Nordisk Valuation After Recent Share Price Volatility

Advertisement Recent performance snapshot Novo Nordisk (NYSE:NVO) has drawn attention after a mixed run in the stock, with a gain of about 15% over the past m...

TipRanks 10h

Novo Nordisk Wins CHMP Backing for High-Dose Wegovy Single-Dose Pen in EU

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, person...

TipRanks 12h

Novo Nordisk Expands Obesity Reach With AMAZE 3 Sleep Apnoea Trial

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask S...

Analyst ratings

57%

of 37 ratings

Buy

35.1%

Hold

56.8%

Sell

8.1%

More NVO News

TipRanks 12h

Novo Nordisk’s AMAZE 4 Trial Targets Obesity and Sleep Apnea for Next Growth Leg

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask S...

TipRanks 19h

Studies suggest Ozempic, Mounjaro may slow tumor progression, WSJ reports

New studies suggest GLP-1 drugs such as Ozempic and Mounjaro, developed by Novo Nordisk (NVO) and Eli Lilly (LLY), may significantly improve cancer outcomes by...

Simply Wall St 1d

Novo Nordisk Turns To OpenAI To Tighten Drug Development And Supply Chain

Novo Nordisk (NYSE:NVO) has announced a new partnership with OpenAI to embed artificial intelligence across drug discovery, manufacturing, and supply chain oper...

MarketWatch 2d

Canada and India now have generic Wegovy. Here’s why the U.S. doesn’t.

There are now highly anticipated generic versions of Novo Nordisk’s GLP-1 blockbusters, Ozempic and Wegovy, on the Canadian market. Several generic versions ha...

The Motley Fool 2d

Could Viking Therapeutics Be the Next Eli Lilly?

Eli Lilly (LLY 0.52%) wasn't the first to conquer the weight loss drug market. Novo Nordisk started the ball rolling back in 2017, when it won approval for its...

Nasdaq 2d

Best Weight Loss Drug Stocks to Buy in 2026

Key Points Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not b...

Simply Wall St 3d

Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors

Novo Nordisk (NYSE:NVO) reported new semaglutide (Wegovy) data at the EASL 2026 congress on liver safety and efficacy in chronic liver disease. The trials focu...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.